Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML

Lisa Rohrbacher, Daniel Nixdorf, Helena Stadler, Bettina Brauchle, Florian Märkl, Nora Philipp, Gerulf Hänel, Anetta Marcinek, Maryam Kazerani, Alica Joana Emhardt, Giulia Magno, Rebecca L. Goldstein, Tobias Straub, Sebastian Kobold, Tara L. Chapman-Arvedson, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3444.

https://doi.org/10.1182/blood-2023-177922

Published: 2023

Journal Articles

Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro

Amelie Muth, Nora Philipp, Anetta Marcinek, Tobias Straub, Lis Winter, Gerulf Hänel, Daniel Nixdorf, Lisa Rohrbacher, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2023-174258

Published: 2023

Journal Articles

Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion

Nora Philipp, Anetta Marcinek, Gerulf Hänel, Daniel Nixdorf, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2023-179286

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

Francesco Corrado, Jan Wulf, Tobias Straub, Daniel Nixdorf, Anetta Marcinek, Nora Philipp, Chang-Feng Chu, Christina Zielinski, Michael von Bergwelt-Baildon, Viktoria Blumenberg, Maryam Kazerani, Marion Subklewe, Veit L. Buecklein

Blood (2023) 142 (Supplement 1): 600.

https://doi.org/10.1182/blood-2023-188970

Published: 2023

Journal Articles

CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML

Yingshuai Wang, Wenjie Lu, Lisa Rohrbacher, Heinrich Flaswinkel, Alica Joana Emhardt, Giulia Magno, Sascha Haubner, Sebastian Kobold, Heinrich Leonhardt, Karl-Peter Hopfner, Dirk H Busch, Veit L. Buecklein, Daniel Nixdorf, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2023-180890

Published: 2023

Journal Articles

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

Lis Winter, Lea Pawlowsky, Anetta Marcinek, Bettina Brauchle, Amelie Muth, Maryam Kazerani, Agnese Petrera, Roman Kischel, Alica Joana Emhardt, Maja Rothenberg-Thurley, Annika Maria Dufour, Karsten Spiekermann, Michael Andreeff, Naval Daver, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2023-173826

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

David M. Cordas dos Santos, Amar Hadzic, Martin E. Kirmaier, Werner Schmitz, Viktoria Blumenberg, Kai Rejeski, Veit L. Buecklein, Michael von Bergwelt-Baildon, Marion Subklewe, Sebastian Theurich

Blood (2023) 142 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2023-186178

Published: 2023

Journal Articles

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Blood (2023) 142 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2023-186510

Published: 2023

Journal Articles

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Viktoria Blumenberg, Maryam Kazerani, Stephan Baumann, Tobias Straub, Francesco Corrado, Jan Wulf, Galina Busch, Kai Rejeski, Lisa Frölich, Christian Schmidt, Michael von Bergwelt-Baildon, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2023-187495

Published: 2023

Journal Articles

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Blood (2022) 140 (Supplement 1): 4549–4551.

https://doi.org/10.1182/blood-2022-167632

Published: 2022

Journal Articles

Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells

Maryam Kazerani, Lucas Wange, Benjamin Tast, Maria Solovey, Daniel Nixdorf, Lisa Rohrbacher, Christina Heitmüller, Thomas Koehnke, Frauke Schnorfeil, Victoria V Grunwald, Karsten Spiekermann, Klaus H. Metzeler, Karl-Peter Hopfner, Wolfgang Enard, Veit L Buecklein, Marion Subklewe

Blood (2022) 140 (Supplement 1): 6321–6322.

https://doi.org/10.1182/blood-2022-167788

Published: 2022

Journal Articles

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Blood (2022) 140 (Supplement 1): 115–117.

https://doi.org/10.1182/blood-2022-158381

Published: 2022

Journal Articles

Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Kai Rejeski, Viktoria Blumenberg, Simon KG Forsberg, Agnese Petrera, Niklas Mueller, Friederike Hildebrandt, Lisa Frölich, Philipp Karschnia, Christian Schmidt, Martin Dreyling, Michael von Bergwelt, Marion Subklewe, Veit L Buecklein

Blood (2022) 140 (Supplement 1): 7421–7422.

https://doi.org/10.1182/blood-2022-167806

Published: 2022

Journal Articles

Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)

Veit L Buecklein, Maximilian Warm, Karsten Spiekermann, Christian Schmidt, Michael Unterhalt, Naval Daver, Marion Subklewe

Blood (2022) 140 (Supplement 1): 3227–3228.

https://doi.org/10.1182/blood-2022-169867

Published: 2022

Journal Articles

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Blood (2022) 140 (Supplement 1): 2411–2413.

https://doi.org/10.1182/blood-2022-165452

Published: 2022

Journal Articles

CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany

Blood (2022) 140 (Supplement 1): 10407–10409.

https://doi.org/10.1182/blood-2022-156775

Published: 2022

Journal Articles

Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy

Kai Rejeski, David M. Cordas dos Santos, Paul Trinkner, Sophie Guenther, Lian Liu, Michael Winkelmann, Veit L Buecklein, Viktoria Blumenberg, Christian Schmidt, Philipp Karschnia, Wolfgang G. Kunz, Michael von Bergwelt, Sebastian Theurich, Marion Subklewe

Blood (2022) 140 (Supplement 1): 10405–10406.

https://doi.org/10.1182/blood-2022-159493

Published: 2022

Journal Articles

The Race Is on: BiTE Vs CART As FLT3-Directed Immunotherapies in AML

Lisa Rohrbacher, Daniel Nixdorf, Helena Stadler, Bettina Brauchle, Florian Märkl, Nora Phillip, Gerulf Hänel, Anetta Marcinek, Maryam Kazerani, Rebecca Goldstein, Michael von Bergwelt, Sebastian Kobold, Veit L Buecklein, Tara Chapman-Arvedson, Marion Subklewe

Blood (2022) 140 (Supplement 1): 10233–10234.

https://doi.org/10.1182/blood-2022-158452

Published: 2022

NARROW

Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML

Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro

Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany

Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy

The Race Is on: BiTE Vs CART As FLT3-Directed Immunotherapies in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only